At SOMAÍ, we are building a leading global brand with the most robust pipeline of innovative cannabis-based therapeutics. We envision a world where people live a healthy lifestyle empowered by natural cannabis medicine.
SOMAÍ owns a state-of-the-art manufacturing facility, SOMAÍ Pharmaceuticals, and indoor cultivation, NovaSoma, in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets.
AIRO BRANDS, Inc. (“Airo”), a U.S. multi-state CPG company focused on proprietary cannabis products, in partnership with Jupiter Research LLC,…
Read moreEn quelques années, le Portugal est devenu le deuxième producteur mondial de cannabis médical. Grâce à sa législation, il attire…
Read moreIn an industry defined by local operators struggling to stay afloat and confined within their borders, Michael Sassano, founder and…
Read moreIn an industry defined by local operators struggling to stay afloat and confined within their borders, Michael Sassano, founder and…
Read moreSOMAÍ chairman and interim CEO Michael Sassano says many Australian producers have work to do before they can compete on…
Read moreAustralia was the first global market to get a taste of Thai flower. The rumour mill is abuzz with local…
Read moreItaly has long been one of the oldest European cannabis markets, which brought access to medical patients since 2015. Although…
Read moreSOMAÍ, a leading EU-GMP vertically integrated Multi-Country Operator (MCO), continues its rapid expansion into key global markets with its official…
Read moreFrom California to Portugal and Thailand, global cannabis raids reveal a persistent and dangerous illicit market—fueled by poor regulation, political…
Read more
“As Germany debates cracking down on tele-clinics and flower sales, all eyes are on patient experience disruptions,” Sassano said.“Reversing course…
Read more
From Wall Street to Lisbon, from real estate to cannabis pharmaceuticals — Michael Sassano’s journey is anything but ordinary. In this…
Read more
As the medical cannabis industry in Australia continues to boom with more patients than ever and the most modern products…
Read more
Switzerland has long been a country that wants to create a safe and sustainable future for its population — and…
Read more
Lisbon, Portugal — [1 July 2025] — SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines,…
Read moreThrowback to Benzinga’s Cannabis Capital Conference in Chicago — where our Founder & Interim CEO, Michael Sassano, sat down for…
Read moreWe’re proud to announce a major milestone: SOMAÍ is partnering with Cookies Creative Consulting & Promotions, Inc. of California (Cookies…
Read more
SOMAÍ has announced the launch of dedicated HCP portals in Australia, Germany, and the United Kingdom, as well as the…
Read more
One of the key differences between medical cannabis and other more traditional treatments is the highly personalised nature of how…
Read moreThailand is already the largest global medical cannabis market, with $1.2 billion in local sales. But that’s not all — Thailand…
Read more
Dan Herer, son of the legendary Jack Herer, partners with Somai Pharmaceuticals to take the Herer standard worldwide. Blending grassroots…
Read more